search icon
btai-img

BioXcel Therapeutics Inc, Common Stock

BTAI

NAQ

$1.39

-$0.03

(-2.11%)

1D
Industry: Biotechnology Sector: Health Care

Analyst Forecast

Price Chart

Key Metrics

Market Cap info-icon
This is a company’s total value as determined by the stock market. It is calculated by multiplying the total number of a company's outstanding shares by the current market price of one share.
$8.30M
P/E Ratio info-icon
This is the ratio of a security’s current share price to its earnings per share. This ratio determines the relative value of a company’s share.
0
Volume info-icon
This is the total number of shares traded during the most recent trading day.
92.41K
Avg Volume info-icon
This is the average number of shares traded during the most recent 30 days.
0
Dividend Yield info-icon
This ratio shows how much income you earn in dividend payouts per year for every dollar invested in the stock (or the stock’s annual dividend payment expressed as a percentage of its current price).
0.00%
Beta info-icon
This measures the expected move in a stock’s price relative to movements in the overall market. The market, such as the S&P 500 Index, has a beta of 1.0. If a stock has a Beta greater (or lower) than 1.0, it suggests that the stock is more (or less) volatile than the broader market.
0.08
52-week Range info-icon
This shows the range of the stock’s price between the 52-week high (the highest price of the stock for the past 52 weeks) and the 52-week low (the lowest price of the stock for the past 52 weeks).
$1.29 L
$31.84 H
$1.39

About BioXcel Therapeutics Inc, Common Stock

BioXcel Therapeutics, Inc., together with its subsidiary, OnkosXcel Therapeutics LLC, operates as a biopharmaceutical company that utilizes artificial intelligence approaches to develop medicines in neuroscience and immuno-oncology in the United States. The company develops its neuroscience candidate, BXCL501, which is an investigational, proprietary, orally dissolving film formulation of dexmedetomidine in development for the treatment of agitation associated with psychiatric and neurological disorders; and its immune-oncology candidate, BXCL 701, which is an investigational oral innate immune activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors. It also develops IGALMI, a sublingual film for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults; BXCL502 for the treatment of stress-related neuropsychiatric symptoms in dementia and other stress-related disorders; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, which has the potential to address apathy and aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut. more

Industry: BiotechnologySector: Health Care

Returns

Time FrameBTAISectorS&P500
1-Week Return1.46%4.61%0.88%
1-Month Return-18.71%1.61%15.35%
3-Month Return-34.74%-8.01%-1.25%
6-Month Return-84.77%-6.48%-0.14%
1-Year Return-95.68%-7.9%11.55%
3-Year Return-99.36%2.89%49.36%
5-Year Return-99.83%35.5%101.11%
10-Year Return-99.21%79.22%178.44%

Financials

Dec '20Dec '21Dec '22Dec '23Dec '245YR TREND
Total Revenue24.30-375.00K1.38M2.27M[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":16.55,"profit":true},{"date":"2023-12-31","value":60.9,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Cost of Revenue188.00K297.00K20.00K1.26M2.14M[{"date":"2020-12-31","value":8.77,"profit":true},{"date":"2021-12-31","value":13.86,"profit":true},{"date":"2022-12-31","value":0.93,"profit":true},{"date":"2023-12-31","value":58.8,"profit":true},{"date":"2024-12-31","value":100,"profit":true}]
Gross Profit24.30(297.00K)355.00K120.00K123.00K[{"date":"2020-12-31","value":0.01,"profit":true},{"date":"2021-12-31","value":-83.66,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":33.8,"profit":true},{"date":"2024-12-31","value":34.65,"profit":true}]
Gross Margin100.00%-94.67%8.70%5.43%[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":94.67,"profit":true},{"date":"2023-12-31","value":8.7,"profit":true},{"date":"2024-12-31","value":5.43,"profit":true}]
Operating Expenses82.30M106.94M160.00M171.90M67.37M[{"date":"2020-12-31","value":47.87,"profit":true},{"date":"2021-12-31","value":62.21,"profit":true},{"date":"2022-12-31","value":93.08,"profit":true},{"date":"2023-12-31","value":100,"profit":true},{"date":"2024-12-31","value":39.19,"profit":true}]
Operating Income(82.30M)(106.94M)(159.65M)(171.78M)(67.25M)[{"date":"2020-12-31","value":-8229700000,"profit":false},{"date":"2021-12-31","value":-10693500000,"profit":false},{"date":"2022-12-31","value":-15964500000,"profit":false},{"date":"2023-12-31","value":-17178200000,"profit":false},{"date":"2024-12-31","value":-6724500000,"profit":false}]
Total Non-Operating Income/Expense256.00K8.00K(11.80M)(13.88M)(4.88M)[{"date":"2020-12-31","value":100,"profit":true},{"date":"2021-12-31","value":3.13,"profit":true},{"date":"2022-12-31","value":-4608.2,"profit":false},{"date":"2023-12-31","value":-5422.27,"profit":false},{"date":"2024-12-31","value":-1906.64,"profit":false}]
Pre-Tax Income(82.17M)(106.93M)(165.76M)(179.05M)(59.60M)[{"date":"2020-12-31","value":-8216900000,"profit":false},{"date":"2021-12-31","value":-10693100000,"profit":false},{"date":"2022-12-31","value":-16575700000,"profit":false},{"date":"2023-12-31","value":-17905300000,"profit":false},{"date":"2024-12-31","value":-5959900000,"profit":false}]
Income Taxes(161.00K)(301.00K)6.09M150.10K-[{"date":"2020-12-31","value":-2.64,"profit":false},{"date":"2021-12-31","value":-4.94,"profit":false},{"date":"2022-12-31","value":100,"profit":true},{"date":"2023-12-31","value":2.46,"profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Income After Taxes(82.01M)(106.63M)(171.85M)(179.20M)-[{"date":"2020-12-31","value":-8200800000,"profit":false},{"date":"2021-12-31","value":-10663000000,"profit":false},{"date":"2022-12-31","value":-17184900000,"profit":false},{"date":"2023-12-31","value":-17920310500,"profit":false},{"date":"2024-12-31","value":"-","profit":true}]
Income From Continuous Operations(82.32M)(106.93M)(165.76M)(211.60M)(59.60M)[{"date":"2020-12-31","value":-8232400000,"profit":false},{"date":"2021-12-31","value":-10693100000,"profit":false},{"date":"2022-12-31","value":-16575700000,"profit":false},{"date":"2023-12-31","value":-21160500000,"profit":false},{"date":"2024-12-31","value":-5959900000,"profit":false}]
Income From Discontinued Operations-----[{"date":"2020-12-31","value":"-","profit":true},{"date":"2021-12-31","value":"-","profit":true},{"date":"2022-12-31","value":"-","profit":true},{"date":"2023-12-31","value":"-","profit":true},{"date":"2024-12-31","value":"-","profit":true}]
Net Income(82.01M)(106.63M)(171.85M)(179.05M)(59.60M)[{"date":"2020-12-31","value":-8200800000,"profit":false},{"date":"2021-12-31","value":-10663000000,"profit":false},{"date":"2022-12-31","value":-17184900000,"profit":false},{"date":"2023-12-31","value":-17905300000,"profit":false},{"date":"2024-12-31","value":-5959900000,"profit":false}]
EPS (Diluted)(3.79)(4.08)(5.91)(6.15)(4.96)[{"date":"2020-12-31","value":-379,"profit":false},{"date":"2021-12-31","value":-408,"profit":false},{"date":"2022-12-31","value":-591,"profit":false},{"date":"2023-12-31","value":-615,"profit":false},{"date":"2024-12-31","value":-496.27,"profit":false}]

Ratios

Liquidity

These ratios help you determine the liquidity of the company. Higher is better.

BTAI
Cash Ratio 1.21
Current Ratio 1.48
Quick Ratio 1.45

Asset Efficiency

These ratios help you understand the company's efficiency in using its assets to generate returns. Higher is better. For ROE, average long term is around 14%, less than 10% is poor.

BTAI
ROA (LTM) -52.47%
ROE (LTM) -1766.94%

Liabilities

These ratios help you understand the company's liabilities, gauging the riskiness of the investment.

BTAI
Debt Ratio Lower is generally better. Negative is bad. 3.34
Common Equity/Total Assets Higher is better. Lower can suggest investment is riskier. -2.34

Valuation

These ratios help you understand the company's valuation. Lower may indicate cheaper stocks.

BTAI
Trailing PE NM
Forward PE NM
P/S (TTM) 4.64
P/B 3.97
Price/FCF NM
EV/R 45.13
EV/Ebitda NM

FAQs

What is BioXcel Therapeutics Inc share price today?

BioXcel Therapeutics Inc (BTAI) share price today is $1.39

Can Indians buy BioXcel Therapeutics Inc shares?

Yes, Indians can buy shares of BioXcel Therapeutics Inc (BTAI) on Vested. To buy BioXcel Therapeutics Inc from India, you can open a US Brokerage account on Vested today by clicking on Sign Up or Invest in BTAI stock at the top of this page. The account opening process is completely digital and secure, and takes a few minutes to complete.

Can Fractional shares of BioXcel Therapeutics Inc be purchased?

Yes, you can purchase fractional shares of BioXcel Therapeutics Inc (BTAI) via the Vested app. You can start investing in BioXcel Therapeutics Inc (BTAI) with a minimum investment of $1.

How to invest in BioXcel Therapeutics Inc shares from India?

You can invest in shares of BioXcel Therapeutics Inc (BTAI) via Vested in three simple steps:

  • Click on Sign Up or Invest in BTAI stock at the top of this page
  • Breeze through our fully digital and secure KYC process and open your US Brokerage account in a few minutes
  • Transfer USD funds to your US Brokerage account and start investing in BioXcel Therapeutics Inc shares
What is BioXcel Therapeutics Inc 52-week high and low stock price?

The 52-week high price of BioXcel Therapeutics Inc (BTAI) is $31.84. The 52-week low price of BioXcel Therapeutics Inc (BTAI) is $1.29.

What is BioXcel Therapeutics Inc price-to-book (P/B) ratio?

The price-to-book (P/B) ratio of BioXcel Therapeutics Inc (BTAI) is 3.97

What is the Market Cap of BioXcel Therapeutics Inc?

The market capitalization of BioXcel Therapeutics Inc (BTAI) is $8.30M

What is BioXcel Therapeutics Inc’s stock symbol?

The stock symbol (or ticker) of BioXcel Therapeutics Inc is BTAI

Signup to access all features and start your US investing journey!

  • Open your account in minutes
  • Take your portfolio global, starting at just $1
Get started

Add ticker to compare

Scroll to Top